Brodalumab Biosimilar - Research Grade

Human

IL-17RA

>1mg/ml

Human IgG2-Kappa

https://www.imgt.org/mAb-DB/

ICH3002

Q96F46;Q16552

Blue ice

This is a research-grade, unconjugated recombinant analog of brodalumab, an anti-IL-17RA antibody, supplied strictly for research use only and not for human or veterinary use. It is a non-therapeutic biosimilar built around the human IL-17 receptor A (IL-17RA) target and formatted as a human IgG2-kappa molecule that reproduces the antigen-binding specificity of the originator, making it a convenient tool for probing IL-17 receptor biology without sourcing clinical material. Typical research applications include use as a binding and blocking reagent against IL-17RA, as an isotype-matched positive control in receptor-engagement and neutralization assays, and as a reference standard when benchmarking in-house anti-IL-17RA antibodies or characterizing IL-17-axis signaling in cell-based systems. Because it is offered at research grade with low endotoxin (typically <1 EU/mg, with ultra-low <0.5 EU/mg options) and in bulk milligram-to-gram quantities, it suits both routine in-vitro work and larger preclinical study designs where lot consistency and cost per mg matter. It is not the clinical drug and carries no therapeutic claims. IL-17RA (interleukin-17 receptor A; UniProt Q96F46) is a broadly expressed type I transmembrane receptor that serves as the shared, central subunit of the IL-17 receptor family. By pairing with different co-receptor chains, it transduces signals for multiple IL-17 family cytokines: with IL-17RC it forms the receptor for IL-17A and IL-17F (UniProt Q16552 corresponds to IL-17A), and it also partners with IL-17RB and IL-17RE for IL-17E/IL-25 and IL-17C signaling. Ligand engagement drives Act1 (CIKS) recruitment via SEFIR domains, activating NF-kB and MAPK pathways and inducing pro-inflammatory mediators, chemokines, and antimicrobial peptides. Because IL-17RA is the obligate hub for several IL-17 cytokines, blocking it interrupts a wider slice of IL-17-axis signaling than neutralizing a single ligand, which underlies its interest in barrier immunity and chronic inflammatory conditions such as psoriasis.

IL-17 receptor A, CDw217, IL-17, IL-17A, Cytotoxic T-lymphocyte-associated antigen 8, CTLA-8, Interleukin-17 receptor A, Interleukin-17A, IL17R

Detects human IL-17RA. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Brodalumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Brodalumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Brodalumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Brodalumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Brodalumab that binds human IL-17RA.